Adamas Finance Asia Limited (LON:ADAM) was the top riser on a hot day for stocks in London, rising 41% to 27.5p.
The company revealed that it increased its net asset value by 8% year-on-year in 2019 to US$100.9mln.
The improvement was driven mostly by a new investment that was acquired in exchange for the issue of the company's shares, said the small business finance specialist.
2.00pm: e-Therapeutics begins experimental testing on coronavirus compounds
e-Therapeutics PLC (LON:ETX) shares rose 17% to 17.88p after it began experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19).
The AIM-listed firm said the initial compound set, which it believes has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.
e-Therapeutics added that it will continue to pursue a network-driven drug discovery approach to identify approved and known drugs that could be “rapidly repositioned” for the treatment of coronavirus.
12.45pm: Jangada Mines hails latest drilling results from Pitombeiras
Jangada Mines PLC (LON:JAN) was lited 6.8% to 1.975p by the drilling results from ts Pitombeiras Vanadium Project in Brazil.
The latest assay results have returned the highest vanadium oxide (V2O5) intercept rates to date at 0.75%.
“On average, the Pitombeiras North Target has shown grades of 0.51% V2O5 over 30.46 metres thickness, mostly starting on or near the surface, on a grid of 50 metres by 100 metres, which brings the level of confidence necessary to delineate our first initial JORC mineral resource estimate in due course," said Brian McMaster, the chairman of Jangada.
11.30am: Cora Gold higher as gold price hardens
Cora Gold Limited (LON:CORA), up 4.5% at 5.75p, received a double boost from the publication of its results and the hardening gold price.
The West Africa-focused gold company said it has a busy schedule of exploration programmes planned once again and is confident that positive news flow will be generated throughout the coming months.
The loss before tax widened to US$1.48mln in 2019 from US$837,000 in 2018, largely as a result of a US$796,000 write-down in the value of intangible assets.
10.30am: Phoenix Copper targeting cash flow from its Red Star mine by end of 2021
Phoenix Copper Limited (LON:PXC) found the market easy to please, with the shares rising 8.1% to 20p after it posted a presentation on its website.
The dual-listed mine developer said it is targeting cash flow from its Red Star silver/lead underground mine by the end of 2021.
Meanwhile, it reminded investors that a feasibility study is underway at its Empire copper/gold/silver deposit.
9.30am: Renalytix eyes NASDAQ IPO
Renalytix AI PLC (LON:RENX) was 7.5% higher at 345p in early trade on Monday after announcing plans to dual-list on the NASDAQ exchange in the US.
The artificial intelligence-enabled in vitro diagnostics company has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission across the pond.
The number of securities to be offered and the price for the proposed offering have not yet been determined.
On May 1, the group announced it had created an operational prototype of an identity documentation exchange system that complies with the general data protection regulations.
Catenae is working with a consortium of companies led by the Z/Yen Group to develop a product that will be marketed to businesses and “other organisations”.
In other coronavirus news, Open Orphan PLCs (LON:ORPH) shares climbed 10% to 14.25p after it confirmed its coronavirus COVID-19 antibody microarray machine is undergoing testing at hVivo's laboratory in east London.
The move follows the companys recently announced tie-up with Quotient Limited. The machine, which will be fully operational in two weeks, can carry out 3,000 tests per day.
In Monday's update, Open Orphan also said it is in discussions with channel partners to secure new business.
Proactive news headlines:
Catenae Innovation PLC (LON:CTEA) said it has begun trialling and finalising its Cov-ID app for tracking coronavirus (COVID-19) contact. On May 1, the group announced it had created an operational prototype of the GDPR-compliant identity documentation exchange system. Catenae is working with a consortium of companies led by the Z/Yen Group to develop a product that will be marketed to businesses and “other organisations”.
Open Orphan PLC (LON:ORPH) has confirmed that its coronavirus COVID-19 Antibody Microarray machine is on-site at hVivo's laboratory in east London and is undergoing testing. The move follows the companys tie-up with Quotient Limited, announced recently. The machine, which will be fully operational in two weeks, can carry out 3,000 tests per day. In Monday's update, Open Orphan also said it is in discussions with channel partners to secure new business.
e-Therapeutics PLC (LON:ETX) shares rose on Monday as the firm said it has begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug discovery (NDD) platform. The AIM-listed firm said the initial compound set, which it believes has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.
Separately, e-therapeutics also clarified arrangements for its upcoming annual general meeting that is still to be held at 11.00am on June 2, 2020. It said that in response to the current coronavirus (COVID-19) pandemic and stay at home measures in place, the 2020 AGM will now be held at 17 Blenheim Office Park, Long Hanborough, Oxfordshire OX29 8LN (which is the Company's registered office) and not at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.
Conroy Gold and Natural Resources PLC (LON:CGNR) has identified new geological and structural features on the Clontibret gold project which it says are important in regard to controls on high gold grades within the deposit. The geophysical survey centred on the Clontibret gold target area where the company proposes to develop its first gold mine. The Clontibret target is one of a series of gold targets on the 65 kilometre district-scale gold trend that the company has discovered, and has been granted licences over, in the Longford-Down Massif in Ireland.
OptioBiotix Health PLC (LON:OPTI) said its revenues in the first three months of the year rose by 928% year-on-year boosted by its partnership agreements. The total invoiced sales of its LPLDL and SlimBiome offerings as ingredients or final product were £407,844, compared to £39,645 in the same period of 2019. On top of those revenues, the company, which is focused on developing compounds to tackle obesity, cardiovascular disease and diabetes, also received proceeds of £162,500 of investment income from the disposal of shares in SkinBioTherapeutics PLC (LON:SBTX). OptiBiotix pointed out that it had signed nine commercial agreements in the first quarter of 2020, with a further four deals in the subsequent months, making a total of 13 agreements for the year to date. These agreements aim to extend the company's geographic reach into 119 countries.
Westminster Group PLCs (LON;WSG) said its aviation security training operations have been graded 'outstanding' in all areas audited by the UK's Civil Aviation Authority (CAA). The CAA's Aviation Security Quality Assurance Framework requires regulator audits and the achievement of pre-determined grades. Only training providers registered with the CAA can provide Department for Transport (DfT) Aviation Security Training. In a statement, Peter Fowler, Westminster's chief executive added: "Training is an important growing revenue stream for Westminster. Whilst the current (coronavirus) COVID-19 pandemic is affecting the aviation industry worldwide, aviation security and training will remain an important and vital element for air travel. As travel restrictions begin to be lifted, we believe our training services will once again be in demand around the world."
Ergomed PLC (LON:ERGO) revealed that its pharmacovigilance division, PrimeVigilance, has signed a collaboration deal with Automation Anywhere, a leader in robotic process automation (RPA), and DataRobot, an enterprise artificial intelligence specialist, to accelerate its intelligent automation strategy. AIM-listed Ergomed said PrimeVigilance had completed a proof of concept and will now implement a cloud software solution to automate specific pharmacovigilance processes. The company noted that the productivity gains made possible by working with Automation Anywhere and DataRobot are expected to deliver organic growth more efficiently with the automation of manual, repetitive processes.
Norman Broadbent PLC (LON:NBB), which returned to profit in 2019, said it has continued to see a healthy increase in net fee income during the current year. Despite coronavirus (COVID-19) lockdown measures affecting the groups markets in March and April, the recruitment and executive search specialist said it recorded a 12% increase in net fee income (NFI) in the first four months of the year compared to the same period of 2019. The group revealed that it saw strong contributions from its Senior Interim Management and Talent Solutions activities, which offset challenging general market conditions for its Board & Leadership Search offerings.
Alliance Pharma PLC (LON:APH) shares rose on Monday as the company highlighted “a return in consumer confidence” in its Chinese market as the world begins to recover from the coronavirus (COVID-19) pandemic. In a statement to be made at the companys annual general meeting on Monday, Alliance Pharma chief executive Peter Butterfield said while the company had seen “some impact on year to date revenues” due to the coronavirus crisis, it had been encouraged by the robustness of its product portfolio and anticipated that trading will be weighted to the second half of the year. The CEO also said that the firms supply chain remained “robust” and that it had not experienced “any significant supply disruption” due to the outbreak.
Adamas Finance Asia Limited (LON:ADAM) revealed that it increased its net asset value by 8% year-on-year in 2019 to US$100.9mln. The improvement was driven mostly by a new investment that was acquired in exchange for the issue of the company's shares, said the small business finance specialist. Portfolio income increased by over 500% year-on-year to US$2.2mln (GBP1.7mln), the AIM-listed group added, due to the continued repositioning of its portfolio, a trend that is expected to continue in 2020.
Coinsilium Group Limited (LON:COIN) said it has been appointed as an advisor to Kesholabs Limited, a Kenya-based venture builder and development studio focused on blockchain innovation and decentralised open finance solutions. The deal, the financial terms of which are confidential, will see Coinsiliums chief executive Eddy Travia join Kesholabs board of advisors while the company itself will provide services including a review of and recommendations for Kesholabs business model, a business and marketing plan, connections to potential blockchain technology partners and investors, and strategic advice on fundraising options and expansion To date, Kesholabs has been developing three applications which it is planning to launch in the East African market within the next three to 12 months.
Directa Plus PLCs (LON:DCTA) revealed that its graphene-based water treatment technology, Grafysorber, has won a notable industry award. Grafysorber received a Technology Innovation Award 2020 from global consultants Frost & Sullivan. Frost & Sullivan, in an accompanying report, described Grafysorber as a “remarkable step toward attaining sustainable and cost-effective environmental remediation.”
Oriole Resources PLC (LON:ORR) said it has received a rebate totalling £165,000 from Her Majesty's Revenue and Customs in relation to a research and development (R&D) tax relief claim in respect of geoscientific advances sought by the company through its exploration programmes. The claim is for the year ended December 31, 2019, and follows the company's successful claims for the previous three years, as a result of which it received a total of around £145,000. The claim is of significantly higher value than those of the previous three years, as a result of enhanced exploration activities undertaken during the period. The funds will be used to progress the companys technical programme in Cameroon.
Collagen Solutions PLC (LON:COS) has revealed that several options remain open as its formal sales process continues, including the sale of the company. In a regulatory statement, the group told investors that it received indications of interest for a potential purchase of the whole company, a potential purchase of part of the business, and a refinancing of the company. “The company looks forward to engaging with relevant parties in a constructive and positive manner with a view to optimising value for shareholders,” Collagen said.
Arkle Resources PLC (LON: ARK) has raised £250,000 via the issue of 33.3mln shares at 0.75p each. The proceeds will be used for further exploration activities at the Stonepark zinc project in County Limerick, Ireland, and to fund other exploration activities, including on the company's 100% owned gold exploration projects. "The high grade of the Stonepark deposit, its relatively shallow depth and its strategic location next door to Glencore's Pallas Green deposit have generated significant interest leading to the transaction, which significantly strengthens Arkle's balance sheet going forward,” Arkle chief executive Patrick Cullen said in a statement.
Midatech Pharma PLC (LON:MTPH) has announced the financial impact of the termination of its MTD201 drug development programme and the closure of its Bilbao operations. The company, which instigated a strategic review of its business earlier this year, decided to terminate studies on MTD201 due to lack of funds. The estimated cash outflow from the termination of the programme and the closure of the Bilbao operations has been put at £4.6mln. The company expects to take non-cash impairments of £12.3mln.
Vast Resources PLC (LON:VAST) haRead More – Source